Momentum Biotechnologies

Momentum Biotechnologies is a drug discovery partner that delivers innovative mass spec solutions to overcome research challenges for biopharma clients globally. Our core team of scientists and engineers started working together developing the RapidFire high-throughput MS platform and have been serving clients with MS-based services since 2004 including PureHoney Technologies (2015-23). Momentum Biotechnologies goal is to accelerate our partners drug discovery & development programs through superior mass spec based CRO services. We help clients identify and characterize leads for degraders, molecular glues, protein-protein interaction (PPI) disrupters, RNA binders and other target classes. We use innovative techniques including affinity selection MS...

Drug discovery contract research,label free screening using native substrates,mass spectrometry,biochemical assays,enzymology & characterization of targets,custom assay development,hit-to-lead services,hit identification,fragment-based screens,lpxc screens,asms,covalent protein modification,hplc-ms,icp-ms,proteomics,chemoproteomics,peptide mapping,cro,mass spec,and molecular glue

Momentum biotechnologies operates in the Biotechnology research industry.

Momentum biotechnologies's revenue is 11m - 100m

Momentum biotechnologies has 11 - 50 employees.